Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the <scp>PIONEER</scp> 1 Trial

Estimands using the treatment policy strategy for addressing intercurrent events are common in Phase III clinical trials. One estimation approach for this strategy is retrieved dropout whereby observed data following an intercurrent event are used to multiply impute missing data. However, such methods have had issues with variance inflation and model fitting due to data sparsity. This paper introduces likelihood-based versions of these approaches, investigating and comparing their statistical properties to the existing retrieved dropout approaches, simpler analysis models and reference-based multiple imputation. We use a simulation based upon the data from the PIONEER 1 Phase III clinical trial in Type II diabetics to present complex and relevant estimation challenges. The likelihood-based methods display similar statistical properties to their multiple imputation equivalents, but all retrieved dropout approaches suffer from high variance. Retrieved dropout approaches appear less biased than reference-based approaches, resulting in a bias-variance trade-off, but we conclude that the large degree of variance inflation is often more problematic than the bias. Therefore, only the simpler retrieved dropout models appear appropriate as a primary analysis in a clinical trial, and only where it is believed most data following intercurrent events will be observed. The jump-to-reference approach may represent a more promising estimation approach for symptomatic treatments due to its relatively high power and ability to fit in the presence of much missing data, despite its strong assumptions and tendency toward conservative bias. More research is needed to further develop how to estimate the treatment effect for a treatment policy strategy.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Statistics
Published
2025-03-01
DOI
https://doi.org/10.1002/pst.2472
Citations
12
Primary Topic
Advanced Causal Inference Techniques
Type
article
Field-Weighted Citation Impact
31.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial

Marian Mitroiu, Marcel Wolbers, Thomas Drury, Christian Bressen Pipper et al.
12 citations
Pharmaceutical Statistics
Advanced Causal Inference Techniques
31.56
article

Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial

Marian Mitroiu, Marcel Wolbers, Thomas Drury, Christian Bressen Pipper, Khadija Rantell, Tobias Mütze, Lorenzo Guizzaro, James Bell, David Wright
article en
12 citations

Abstract

Estimands using the treatment policy strategy for addressing intercurrent events are common in Phase III clinical trials. One estimation approach for this strategy is retrieved dropout whereby observed data following an intercurrent event are used to multiply impute missing data. However, such methods have had issues with variance inflation and model fitting due to data sparsity. This paper introduces likelihood-based versions of these approaches, investigating and comparing their statistical properties to the existing retrieved dropout approaches, simpler analysis models and reference-based multiple imputation. We use a simulation based upon the data from the PIONEER 1 Phase III clinical trial in Type II diabetics to present complex and relevant estimation challenges. The likelihood-based methods display similar statistical properties to their multiple imputation equivalents, but all retrieved dropout approaches suffer from high variance. Retrieved dropout approaches appear less biased than reference-based approaches, resulting in a bias-variance trade-off, but we conclude that the large degree of variance inflation is often more problematic than the bias. Therefore, only the simpler retrieved dropout models appear appropriate as a primary analysis in a clinical trial, and only where it is believed most data following intercurrent events will be observed. The jump-to-reference approach may represent a more promising estimation approach for symptomatic treatments due to its relatively high power and ability to fit in the presence of much missing data, despite its strong assumptions and tendency toward conservative bias. More research is needed to further develop how to estimate the treatment effect for a treatment policy strategy.

Pharmaceutical StatisticsVol. 24(2)
AstraZeneca (United Kingdom) (GB), Roche (Switzerland) (CH), Novartis (Switzerland) (CH), European Medicines Agency (NL), University of Southern Denmark (DK), GlaxoSmithKline (United Kingdom) (GB), Novo Nordisk (Denmark) (DK), Biogen (Switzerland) (CH)
Openalex Percentile: Top 0%
Advanced Causal Inference Techniques
31.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.